High levels of adenosine known to stimulate tumor immunoevasion are formed by the ecto-5’-nucleotidase enzyme (CD73) conversion of adenosine monophosphate to adenosine. CD73 is a cell surface enzyme that is overexpressed in many cancer types where this overexpression has been correlated with a poor prognosis.
Researchers from Jacobio Pharmaceuticals Co. Ltd. have reported preclinical data for JAB-X1800, an immunostimulatory antibody-drug conjugate (iADC) targeting CD73. JAB-X1800 was developed using an anti-CD73 monoclonal antibody (MAb) for targeted delivery of a highly potent noncyclic dinucleotide STING agonist payload, JAB-27670.
The infiltration of regulatory T cells (Tregs) into the tumor microenvironment and a low ratio of effector T cells to Tregs is usually tied to tumor progression and poor prognosis. On the other hand, interleukin-2 receptor subunit α (IL-2-RA) is highly expressed on Tregs.
Differences in the immune reactions between smokers and nonsmokers may explain why only 20% of patients with lung cancer respond to immunotherapy treatment. Understanding these differences in the evolution of lung cancer between smokers and nonsmokers could be the key to unlocking new treatments.
At the recently concluded AACR meeting, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. discussed BSA-01, a bispecific antibody-drug conjugate (ADC) targeting both epidermal growth factor receptor (EGFR) and mucin-1 (MUC-1), two tumor-associated antigens that are highly co-expressed in several cancers.
RSS
